Traditionally, patients can hear about relevant trials from their physician or search a corresponding database, like the national US registry of clinical studies
. These sources are not sufficient, as doctors are not aware of all the ongoing trials and patients might find scrolling over governmental websites overwhelming, especially given their recent diagnosis.
Enhancing clinical trials with AI allows for sifting through patient data, such as EHR and medical imaging, to compare patient characteristics to the study’s eligibility criteria to identify the right individuals for this particular trial. AI is powerful enough to select a homogeneous set of participants, which is challenging with the conventional methods.
An AI startup Deep Lens
uses its vast database of oncology studies to recruit patients for trials. The startup can match people newly diagnosed with cancer and speed up their enrollment in trials. While 23andMe
, a personal genetics company based in California, suggests clinical studies to its clients based on their genetic makeup.